On May 3, 2018 Volitionrx Limited (NYSEAMERICAN:VNRX) Sellers Rose Their Shorts By 10.62%

May 3, 2018 - By Maria Fierro

VolitionRx Limited (NYSEAMERICAN:VNRX) Corporate Logo

Big Money Sentiment decreased to 1.2 in 2017 Q4. It has change of 5.80, from 2017Q3’s 7. The ratio fall due to VolitionRx Limited positioning: 3 sold and 2 reduced. 2 funds amassed positions and 4 increased positions. Investors holded 9.30 million in 2017Q3 but now own 4.52 million shares or 51.36% less.
Creative Planning reported 13,200 shs. Bridgeway Mgmt Inc stated it has 0% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX). Northern Tru Corp reported 22,714 shs. Brown Brothers Harriman & holds 0% or 3,823 shs. Knoll Cap Ltd Partnership holds 351,538 shs or 0.91% of its capital. Lagoda Investment Management L P has 3.52M shs. 11,219 were accumulated by Blackrock Inc. Bank Of Ny Mellon stated it has 0% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX). Moreover, Garrison Bradford Associates has 0.04% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Bessemer Group Inc reported 10,000 shs stake. Vanguard Gru Inc stated it has 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Leisure Cap Management reported 0.18% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX). Royal Bankshares Of Canada owns 14,007 shs. The New York-based Morgan Stanley has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). The Massachusetts-based Geode Cap Mngmt Lc has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX).

Volitionrx Limited (NYSEAMERICAN:VNRX) registered an increase of 10.62% in short interest. In May was published VNRX’s total 408,300 short interest by FINRA. That’s 10.62% up from 369,100 shares. Volitionrx Limited (NYSEAMERICAN:VNRX) has 160,800 shares average volume. It’ll cost 3 days for VNRX to recover its former position. Volitionrx Limited’s short interest float is 2.23%.

The stock increased 0.34% or $0.0068 during the last trading session, hitting $2.0168.VolitionRx Limited has volume of 8,457 shares. Since May 3, 2017 VNRX has declined 42.82% and is downtrending. VNRX underperformed by 54.37% the S&P 500.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers.The firm is valued at $60.54 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform.Last it reported negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: